Malarone-donation programme in Africa

Lancet

Volumn 350, Issue 9091, 1997, Pages 1624-1625

  Bloland, Peter B ^a,f   Kazembe, Peter N ^b   Watkins, William M ^c   Doumbo, Ogobara K ^d   Nwanyanwu, Okey C ^e   Ruebush II, Trenton K ^a  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^b Lilongwe Central Hospital   (Malawi)

^c KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

^d UNIVERSITY OF BAMAKO   (Mali)

^e U States Agy for Intl Development   (Malawi)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ATOVAQUONE; CHLOROQUINE;

AFRICA; HEALTH CARE AVAILABILITY; HEALTH PROGRAM; MALARIA; PREGNANCY; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0031590620     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)06082-0     Document Type: Note

References (11)

1. Looareesuwan S, Viravan C, Webster HK, et al. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am J Trop Med Hyg 1996; 54: 62-66.
2. Radloff PD, Philipps J, Nkeyi M, et al. Atovaquone and proguanil for Plasmodium falciparum malaria. Lancet 1996; 347: 1511-13.
3. Radloff PD, Philipps J, Hutchinson D, Kremsner PG. Atovaquone plus progranil is an effective treatment for Plasmodium ovale and P malariae malaria. Trans R Soc Trop Med Hyg 1996; 90: 682.
4. White N. Artemisinin: proceedings of a meeting convened by the Wellcome Trust: summary of discussion and conclusions. Trans R Soc Trop Med Hyg 1994; 88: 63-65.
5. World Health Organization. The role of artemisinin and its derivatives in the current treatment of malaria (1994-1995). Report of an informal consultation convened by WHO in Geneva 27-29 September 1993. WHO/MAL/94.1067, Geneva, 1994.
6. Nwanyanwu OC, Ziba C, Kazembe P, et al. Efficacy of suplhadoxine/ pyrimethamine for Plasmodium falciparum malaria in Malawian children under five years of age. Trop Med Intl Health 1996; 1: 231-35.
7. Plowe CV, Djimde A, Wellems TE, Diop S, Kouriba B, Doumbo OK. Community pyrimethamine-sulfadoxine use and prevalence of resistant Plasmodium falciparum genotypes in Mali: a model for deterring resistance. Am J Trop Med Hyg 1996; 55: 467-71.
8. Trigg JK, Mbwana H, Chambo O, Hills E, Watkins W, Curtis CF. Resistance to pyrimethamine-sulfadoxine in Plasmodium falciparum in 12 villages in North East Tanzania and a test of chloroproguanil-dapsone. Acta Trop 1997; 63: 185-89.
9. Bruce-Chwatt LJ. Chemotherapy of malaria. Second edition. World Health Organization, Geneva, 1986.
10. Bloland PB, Lackritz EM, Kazembe PN, et al. Beyond chloroquine: implications of drug resistance for evaluating malaria therapy efficacy and treatment policy in Africa. J Infect Dis 1993; 167: 932-37.
11. Schultz LJ, Steketee RW, Macheso A, et al. The efficacy of antimalarial regiments containing sulfadoxine-pyrimethamine and/or chloroquine in preventing peripheral and placental Plasmodium falciparum infection among pregnant women in Malawi. Am J Trop Med Hyg 1994; 51: 515-22.